Communication Can Mean More to Hypersomnia Patients Than a Label
How evolving diagnoses and unclear terminology can undermine patient trust—and what clinicians can do about it.
Tag: Narcolepsy
All
Latest
All
Latest
Narcolepsy Network Appoints New Executive Director
She brings over 20 years of nonprofit leadership and personal rare disease experience to guide the patient advocacy group.
All
Latest
FDA Approves First Non-Scheduled Drug for Cataplexy in Pediatric Narcolepsy Patients
The treatment was previously approved for excessive daytime sleepiness in pediatric patients 6 years of age and older with narcolepsy.
Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth
The low-sodium oxybate oral solution generated $1.7 billion in revenue, contributing to the company’s $3.1 billion neuroscience portfolio performance in 2025.
Read More
Japan Grants Orphan Drug Designation to Eisai’s Novel Orexin Agonist for Narcolepsy
E2086, a selective orexin 2 receptor agonist, aims to address the pathophysiology of narcolepsy by activating orexinergic neurons.
Read More
Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio
The acquisition accelerates Alkermes’ entry into the sleep medicine market and incorporates the FDA-approved extended-release sodium oxybate treatment for narcolepsy.
Read More
FDA Grants Priority Review to Takeda’s Oveporexton for Narcolepsy Type 1
The investigational oral OX2R-selective agonist is designed to restore orexin signaling; the FDA has set a target action date for the third quarter of 2026.
Read More
Amneal Receives FDA Approval for Sodium Oxybate Oral Solution
The approval allows Amneal to offer a generic alternative for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients, expanding access to this standard of care therapy.
Read More
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026
The company’s narcolepsy treatment shows strong growth, while its late-stage pipeline advances with five phase 3 trials and a novel orexin agonist.
Read More
Avadel Shareholders Approve Acquisition by Alkermes
The deal will bring the narcolepsy treatment LUMRYZ under the Alkermes portfolio.
Read More
Axsome to Submit New Drug Application for Narcolepsy Treatment AXS-12
The upcoming submission for AXS-12 (reboxetine) for cataplexy in narcolepsy follows supportive feedback from the FDA.
Read More
FDA Grants Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1
The designation for the investigational oral orexin 2 receptor agonist aims to expedite development based on positive phase 2 clinical trial data.
Read More
Centessa’s Orexin Agonist ORX750 Shows Efficacy in Narcolepsy, IH Trials
The company also announced a CEO transition to sharpen its focus on its orexin pipeline as phase 2a data shows ORX750 improved key measures of wakefulness and cataplexy.
Read More
Harmony Advances Pitolisant GR After Bioequivalence Success
Positive trial results position the next-generation pitolisant formulation for a New Drug Application in early 2026.
Read More
Takeda Expands AI Partnerships to Scale Narcolepsy Care
The pharmaceutical giant deepens collaboration with Beacon Biosignals and partners with EnsoData to address challenges in narcolepsy type 1.
Read More
Harmony Advances First Human Study of Orexin 2 Agonist
BP1.15205 enters phase 1 testing as Harmony positions the selective OX2R agonist to broaden treatment choices for narcolepsy and other hypersomnolence disorders.
Read More
Alkermes Shares Phase 2 Results of Orexin 2 Receptor Agonist in Narcolepsy Type 2
Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor agonist in phase 2 development for the treatment of narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
Read More
The Overlooked Narcolepsy Symptom
A man in his 40s sat in front of clinical psychologist Christopher Wendel, PhD, DBSM, one early afternoon on the grey couch where Wendel sees all his behavioral sleep therapy clients. “What brings you in?” Wendel asked.
Read More